{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fae-management-for-her3-targeted-tx-STkudeTi","width":444,"version":"1.0","type":"rich","title":"Current Considerations for Adverse Event Management With HER3-Directed Agents","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/24a2742f-cbca-48cb-89ad-b97f34dc276f/lung-her3-prp7140-pod774-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/b6a9650d-6a45-4ab9-b664-72edd50d9a0b\" height=\"200\" width=\"100%\" title=\"Current Considerations for Adverse Event Management With HER3-Directed Agents\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast, Rebecca S. Heist, MD, MPH, discusses the safety profile and management of potential adverse events associated with HER3-directed therapies in lung cancer. "}